Accessibility settings

Published on in Vol 14 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/85809, first published .
Woman uses smartphone with accessibility features and braille display in park

Mobile Health Apps for Individuals Who Are Blind or Have Low Vision: Systematic Review of Evidence, Accessibility, and App Quality

Mobile Health Apps for Individuals Who Are Blind or Have Low Vision: Systematic Review of Evidence, Accessibility, and App Quality

1Research Center for Behavior Assessment (CRAMC), Department of Psychology, Universitat Rovira i Virgili, Carretera de Valls s/n, Tarragona, Catalonia, Spain

2Unit for the Study and Treatment of Pain–ALGOS, Chair in Pediatric Pain, Tarragona, Catalonia, Spain

3Institut d’Investigació Sanitària Pere Virgili, Tarragona, Catalonia, Spain

Corresponding Author:

Jordi Miró, PhD


Background: Individuals who are blind or have low vision experience disproportionate burdens in both physical and psychological functioning, and mobile health apps may help address some of these needs. However, their availability, accessibility, and empirical support for this population remain unclear.

Objective: This systematic review aimed to identify mobile health apps relevant to supporting physical and psychological functioning in individuals who are blind or have low vision, summarize the empirical evidence available for these apps, and examine their accessibility and quality.

Methods: We used a multicomponent approach that combined (1) identification of apps through organizational recommendations; (2) a systematic search of the scientific literature, conducted and reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines; and (3) an exploratory accessibility and app quality appraisal using the Web Content Accessibility Guidelines 2.1 and the Mobile App Development and Assessment Guide.

Results: A total of 19 unique mobile health apps were identified after combining and deduplicating apps identified through organizational recommendations and scientific literature. Fifteen apps were identified through organizational recommendations, and 14 empirical studies evaluating 11 apps were included in the qualitative synthesis. Only a subset of these studies specifically involved blind or low-vision participants; several evaluated apps in broader clinical or general populations where visual impairment status was not reported. The identified apps focused primarily on physical functioning, particularly medication management, glucose monitoring, pharmaceutical information access, and health care access. No apps primarily designed to support psychological functioning in individuals who are blind or have low vision were identified. Of 14 studies, 6 (43%) were rated as being of good methodological quality. The exploratory user-informed accessibility appraisal showed variability across apps: MyPills received the most favorable accessibility profile, with “High” ratings across all 4 Web Content Accessibility Guidelines principles, whereas several organizationally recommended apps received low ratings across most principles. Mobile App Development and Assessment Guide scores ranged from 8/39 to 34/39, with Medisafe scoring highest.

Conclusions: The current landscape of mobile health apps for individuals who are blind or have low vision remains limited, uneven in accessibility and quality, and supported by a limited and heterogeneous evidence base. The absence of identified apps targeting psychological functioning represents a particularly important gap. Improving the development and implementation of mobile health apps for individuals who are blind or have low vision will require more than increasing the number of available apps; it will require apps that are accessible from the outset, rigorously evaluated, and developed with the people they are intended to serve.

Trial Registration: PROSPERO CRD42023448243; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023448243

JMIR Mhealth Uhealth 2026;14:e85809

doi:10.2196/85809

Keywords



In 2019, the World Health Organization estimated that at least 2.2 billion people worldwide are blind or have low vision [1], and the number of individuals living with blindness is projected to reach 115 million by 2050. Visual impairment is therefore a major global public health issue with substantial implications for health, functioning, and quality of life [2].

Research consistently shows that individuals who are blind or have low vision report poorer physical and mental health outcomes than their sighted peers [3-6]. For example, a recent review [7] concluded that chronic pain, particularly neuropathic ocular pain and back pain, appears to be common in this population. Visual impairment is also a well-established risk factor for falls and fractures [8,9], which may in turn contribute to loss of independence, permanent disability, and increased mortality, especially in older adults [10]. Mental health outcomes are similarly affected. Adults with visual impairments experience higher rates of depression [11] and anxiety [4] than those with normal vision, and greater severity of visual impairment has also been associated with increased risk of suicidal thoughts and behaviors [12,13].

Despite the elevated risks, access to health care remains limited for individuals with disabilities, including those with visual impairments [14]. Previous research has documented persistent disparities in preventive care, health care usage, and access to appropriate treatment compared with sighted individuals [2,15,16]. For example, although older adults with visual impairments present higher rates of clinically significant depression and anxiety [17], many never receive appropriate treatment [18,19]. Even in settings where accessibility is legally mandated, implementation is inconsistent [20]. Access to effective treatment is further restricted by the limited accessibility of many medical technologies. For example, insulin pumps and other diabetes-related devices often lack basic accessibility features such as voice guidance and accessible instructions [21], despite the relevance of diabetes in this population.

Mobile health apps (ie, software designed for smartphones, tablets, and other portable devices [22]) have emerged as promising tools to support the management of chronic noncommunicable diseases, such as chronic pain [23,24], diabetes [25], hypertension [26], depression [27], and anxiety [28]. For individuals who are blind or have low vision, mobile apps can promote autonomy, enhance communication with health care professionals and peers, and improve personalized care and overall quality of life [29-33]. However, many commercially available apps are developed primarily for commercial rather than clinical purposes and lack rigorous empirical support [34]. Limited involvement of key stakeholders, particularly end users [35], may further contribute to mistrust, privacy concerns, and the dissemination of inaccurate or even potentially harmful information [36,37]. Some reviews and empirical studies have begun to describe the broader landscape of mobile app usability for visually impaired users. For example, Al-Razgan and colleagues [29] conducted a systematic literature review on the usability of mobile apps for people with visual impairments, identifying key themes such as accessibility, assistive technologies, navigation, and interaction design. Their review provides an important overview of the general usability challenges faced by visually impaired users in mobile environments. However, mobile health apps, particularly those intended to support the physical and psychological functioning of individuals who are blind or have low vision, received far less systematic attention.

To our knowledge, no systematic review has specifically examined mobile health apps relevant to individuals who are blind or have low vision with a focus on their potential role in supporting physical and psychological functioning, the empirical evidence supporting their use, and the extent to which such apps meet current accessibility and quality standards. Conducting such a review has important implications for both research and clinical practice: it can help identify promising tools, clarify important gaps in the evidence base, and inform the development and recommendation of apps that are both effective and accessible for this population.

Accordingly, this systematic review addressed three research questions: (1) Which mobile health apps relevant to individuals who are blind or have low vision can be identified through organizational recommendations and the scientific literature? (2) What empirical evidence is available regarding the usability, accessibility, and health-related outcomes of these apps? (3) What do the exploratory user-informed accessibility appraisal and app-quality assessment suggest about the accessibility and quality of the identified apps?


Procedure

Overview

This study followed a multicomponent review design intended to address complementary dimensions of the same research problem. First, we identified mobile health apps recommended by organizations serving individuals who are blind or have low vision in order to characterize apps currently promoted within this community. Second, we conducted a systematic review of the scientific literature to identify and examine empirical studies evaluating mobile health apps relevant to this population. Apps identified through organizational recommendations and the scientific literature were then combined and deduplicated by app name, developer, intended function, and platform availability to determine the final number of unique apps included in the review. This review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [38] for systematic reviews and meta-analyses and was conducted in accordance with the preregistered protocol in the PROSPERO [39] database (CRD42023448243). No substantive deviations from the protocol occurred; any minor refinements were limited to improvements in reporting clarity and did not affect the scope, eligibility criteria, or analytical approach. All studies were analyzed using a qualitative synthesis approach. Two independent reviewers (CM and JM) assessed study eligibility using a 2-step process that involved initial screening of titles and abstracts followed by full-text evaluation. Discrepancies were resolved through discussion, and when necessary, a third reviewer was consulted to reach consensus. Third, we carried out an exploratory, user-informed accessibility appraisal of apps that were available for direct review. This final component was not designed as a stand-alone primary study or as a formal usability trial intended for statistical generalization but rather as a complementary appraisal to provide practical insight into how the identified apps could be accessed and experienced by potential users. Accordingly, the accessibility appraisal was intended to contextualize the evidence synthesis by bridging the gap between published descriptions of apps and their real-world accessibility in use. As this review was based exclusively on previously published literature and did not involve the collection of primary data or direct participation of human subjects, approval from an Institutional Review Board (IRB) or Research Ethics Committee was not required.

Identification of Apps Recommended by Organizations Serving Individuals With Visual Impairments

To identify mobile health apps currently recommended to individuals who are blind or have low vision, we conducted a targeted review of websites and digital resources from organizations serving this population. These organizations often act as key sources of information and dissemination channels for assistive technologies and digital tools within the visually impaired community. Organizations from different geographical regions were considered, including international, national, and regional organizations that provide resources and support for individuals with visual impairments. Examples include the American Foundation for the Blind, the Royal National Institute of Blind People, the World Blind Union, the Spanish National Organization for the Blind (ONCE), and Vision Australia. The websites of these organizations were systematically examined to identify mobile health apps intended to support physical and psychological functioning in individuals who are blind or have low vision and those that were recommended or listed as potentially useful for this population. When relevant information was available, we recorded basic descriptive characteristics of each app, including the app name, platform availability (ie, iOS or Android), intended purpose, and any description provided by the recommending organization.

Systematic Search of the Scientific Literature on Mobile Health Apps Intended to Support Physical and Psychological Functioning

To identify empirical studies on mobile health apps intended to support the physical and psychological functioning of individuals who are blind or have low vision, we conducted a systematic search of the scientific literature. The search was performed in 3 major databases: ScienceDirect, PubMed or MEDLINE, and other National Center for Biotechnology Information (NCBI) resources. The search strategy combined terms related to mobile apps and visual impairment. Specifically, the following keywords were used: (“app*” OR “mobile” OR “smartphone”) AND (“visually impaired” OR “visual disability” OR “blind*” OR “low vision” OR “ocular*” OR “eye*”), using asterisks as wild cards to capture variations of each term. A supplementary app-name search was also conducted for apps identified through organizations serving individuals with visual impairments, combined with the same keyword strategy. The initial search was conducted in ScienceDirect, PubMed or MEDLINE, and other NCBI resources and covered records published through December 2025. In April 2026, the search was updated and extended across all 6 databases included in the final review: ScienceDirect, PubMed or MEDLINE, PubMed Central, Scopus, Web of Science, and the ACM Digital Library. All 6 databases were searched from inception through April 2026. Thus, the April 2026 update both extended the final coverage date of the databases included in the initial search and broadened database coverage by adding Scopus, Web of Science, and the ACM Digital Library. The updated search strategy was developed through an iterative refinement process. Initial exploratory searches using broad terms yielded a high proportion of irrelevant records due to the ambiguity of certain keywords. Therefore, search terms were progressively refined by prioritizing more specific descriptors related to mobile apps and visual impairment and by combining these with methodological terms (eg, “evaluation” and “empirical study”) where appropriate. This approach aimed to balance sensitivity and specificity, ensuring adequate coverage while reducing noise. The search was restricted to peer-reviewed journal papers. Gray literature and conference proceedings were not included as primary evidence sources, as the review focused on empirical studies with formal evaluation components to ensure methodological consistency and comparability across studies. The full database-specific search strategies used in the updated search, including complete search strings, Boolean operators, filters, and records retrieved per source, are provided in Multimedia Appendix 1. The supplementary app-name search was intended to identify empirical studies on apps already recommended in practice, while the broader database search aimed to capture additional relevant apps not identified through organizational sources.

To maximize comprehensiveness, we also manually screened the reference lists of eligible papers for additional studies. Studies were included if they met the following criteria: (1) evaluated a mobile app intended as relevant to individuals who are blind or have low vision, because it was designed for this population, recommended by organizations serving this population, or identified in the scientific literature as potentially relevant; (2) reported empirical findings related to the app; (3) were published in a peer-reviewed journal; (4) were available in full text; and (5) were written in English or Spanish. Studies were eligible even when the empirical evaluation was conducted in a broader clinical or general population, provided that the app itself had been identified as relevant to individuals who are blind or have low vision. Data extraction was performed using a structured template developed for this review. Extracted variables included study characteristics (authors, year, country, and design), participant characteristics, app name and purpose, health domain addressed, key accessibility and usability findings, and the main outcomes reported. Study designs were categorized into broader groups (eg, observational and experimental) to facilitate consistent reporting and comparison across heterogeneous studies. The data extraction form used in this review, including all extracted variables, is provided in Multimedia Appendix 2.

Assessment of Methodological Quality and Risk of Bias

Methodological quality and risk of bias were assessed by 2 reviewers (CM and JM) using the version of the National Institutes of Health (NIH) Quality Assessment Tool appropriate to each study design. Discrepancies were discussed and resolved by consensus following guidance from the Cochrane Handbook for Systematic Reviews of Interventions. The final ratings for all included studies were based on this consensus process.

For each study, the NIH criteria were rated as “yes,” “no,” “cannot determine,” or “not applicable,” as appropriate. “Cannot determine” was used when insufficient information was available to judge an item, and “not applicable” when a criterion was not relevant to the study design. To obtain an overall indicator of methodological rigor, “yes” responses were scored as 1 point, whereas all other responses (“no,” “not reported,” “cannot determine,” or “not applicable”) were scored as 0, and item scores were summed across criteria. Consistent with approaches used in previous systematic reviews [40-42], total scores were categorized as poor (0‐6), fair (7-10), or good (11-14). For ease of interpretation, the resulting ratings are presented both at the item level and as an overall summary classification.

Exploratory Accessibility and Functionality Appraisal of the Identified Mobile Apps

This appraisal was conceived as an exploratory complement to the review. Consequently, the resulting ratings should be interpreted as illustrative observations derived from participant experiences and consensus discussions rather than as a formal usability study or as independently generalizable evidence. The accessibility and functionality of the identified apps were appraised using the Web Content Accessibility Guidelines (WCAG 2.1, 2018) [43] framework focusing on the 4 POUR principles: (1) Perceivable (ie, information and user interface elements must be easily perceivable by users), (2) Operable (ie, all elements should be fully interactive, free of distracting animations, or gestures that require the use of multiple fingers), (3) Understandable (ie, information and interface functions should be clear and easy to understand), and (4) Robust (ie, apps should be compatible with different devices and operating systems, including features such as adjustable font sizes). In practical terms, the accessibility appraisal examined whether relevant app information and interface elements were perceivable (eg, accessible labels, readable content, and discernible feedback), whether navigation and controls were operable (eg, keyboard or screen-reader accessibility, predictable navigation, and actionable controls), whether content and interaction flows were understandable (eg, clarity of instructions, consistency, and comprehensibility of interface elements), and whether the app appeared robust in its compatibility with assistive technologies and platform accessibility services. Although WCAG was originally developed for web content, its principles have also been applied and adapted to mobile and nonweb software environments in World Wide Web Consortium (W3C) guidance and prior accessibility research [43,44]. Because some WCAG wording is web-oriented, criteria were interpreted in relation to mobile app environments following established W3C guidance for nonweb Information and Communication Technologies and mobile apps. Thus, references to web pages were considered at the level of app screens or views, and accessibility judgments were made in relation to native app interactions and compatibility with mobile assistive technologies. Following this approach, we applied WCAG 2.1 to native mobile apps to assess barriers and facilitators relevant to individuals who are blind or have low vision, particularly those related to screen reader compatibility, interface clarity, navigation, and interaction with core app functions.

To assess the accessibility and functionality of the identified apps, we conducted a user-based appraisal guided by the WCAG 2.1 framework. Four adult volunteers with visual impairments participated in the evaluation (2 blind and 2 with reduced visual acuity). Participants were recruited through convenience sampling based on accessibility and prior experience using mobile assistive technologies. No formal inclusion or exclusion criteria were applied beyond having lived experience of visual impairment and familiarity with smartphone use. Participants were instructed to download, install, and test the core functionalities of each app (eg, setting medication reminders and navigating menus) using the native accessibility features available on their devices. Following individual testing, participants discussed their experiences in a group session and appraised each app in terms of ease of use, clarity of information, compatibility with screen readers or other assistive technologies, and overall performance across the 4 WCAG principles. Based on this process, each app received an overall rating of low, moderate, or high for each WCAG principle. When disagreement occurred, the most stringent rating was retained in order to prioritize barriers encountered by blind users. These ratings therefore reflect a consensus-based synthesis of the participants’ practical experience with the apps rather than a formal psychometric assessment, standardized accessibility measurement, or clinical evaluation. No interrater reliability, test-retest reliability, or formal validation procedure was conducted for this exploratory component. A detailed operationalization of WCAG 2.1 principles, including examples, is provided in Multimedia Appendix 3. In addition, we reviewed scientific literature related to the accessibility and functionality of the identified apps to complement the user-based appraisal. Given the small and diagnostically homogeneous sample, this component was intended to enrich the review with real-world end user perspectives rather than to generate generalizable estimates of usability.

App Quality Appraisal Using the Mobile App Development and Assessment Guide

Each identified app was also appraised using the Mobile App Development and Assessment Guide (MAG) [35]. The MAG is a structured framework developed to support the assessment of mobile health apps across multiple domains relevant to quality, including usability, privacy, security, appropriateness, safety, and technology performance. The guide includes 39 items organized into seven categories: (1) Usability, (2) Privacy Policy Information, (3) Privacy Features, (4) Security, (5) Appropriateness and Suitability, (6) Safety, and (7) Technology Performance [34]. Two independent researchers (CM and PLl-V) reviewed each app against the 39 MAG criteria. Each item was rated as “yes” when the criterion was met, “no” when it was not met, and “not applicable” when the criterion could not reasonably be assessed for a given app. Agreement between reviewers was approximately 90% before consensus discussions. Disagreements were generally minor and primarily reflected different interpretations of individual MAG criteria. These discrepancies were resolved through discussion and consensus review before final scores were assigned. The full list of MAG criteria used in the evaluation is presented in Table 1. In addition to the item-level appraisal, an overall summary score was calculated for each app based on the number of MAG criteria met, in order to facilitate comparison across apps. Because the MAG does not provide predefined cutoff points for interpreting total scores, descriptive score bands were created for this review. Apps meeting approximately two-thirds or more of the MAG criteria were classified as higher app quality (≥27/39), apps meeting approximately one-half to less than two-thirds of the criteria were classified as moderate app quality (20-26/39), and apps meeting fewer than one-half of the criteria were classified as lower app quality (≤19/39). These categories were used only to aid interpretation of the descriptive MAG scores and should not be interpreted as validated MAG thresholds.

Table 1. Mobile App Development and Assessment Guide (MAG) criteria used to appraise the quality of mobile health apps for individuals who are blind or have low vision.
ItemStatementMAG category
1The app was tested by potential users before being made available to the public.Usability
2It is easy to use.Usability
3The app features are adapted to the purposes of the app.Usability
4Functionality is adjusted to the targeted user.Usability
5The app is designed to be accessible for people with physical impairments.Usability
6The app uses lay language that can be easily understood by the targeted user.Usability
7The user can easily access all resources and features.Usability
8The app provides information about the terms and conditions for the use of the app.Privacy Policy Information
9The app provides information about privacy policies.Privacy Policy Information
10The app provides information about commercial agreements with third parties or the absence of them.Privacy Policy Information
11The app informs users if their data must be transferred to third parties for the app to operate.Privacy Policy Information
12The app indicates a recommended user age based on its content.Privacy Policy Information
13The app includes a simple and understandable version of the terms and conditions of use, and privacy policies.Privacy Policy Information
14The app gives a warning when an update influences sensitive data.Privacy Features
15The app provides the option to only collect user data that are essential for the app to operate.Privacy Features
16The app guarantees users\' rights on stored personal data.Privacy Features
17The app provides the user with the option to refuse the transfer of data to third parties.Privacy Features
18The app requires the user to give her or his consent to the terms and conditions of use and privacy policies.Privacy Features
19The app notifies the user when other resources on the mobile device, such as her or his accounts or social network profiles, are accessed.Privacy Features
20The app guarantees the user’s privacy.Privacy Features
21The app offers to delete the user’s data at any time.Privacy Features
22The app informs the user about the security measures in place.Security
23The app includes password management mechanisms.Security
24The authorization and authentication mechanisms work correctly.Security
25The app validates the user’s identity to access confidential data.Security
26The app informs the user when it detects and identifies cybersecurity vulnerabilities, possible threats, and the risk of being exploited that may affect the data.Security
27The app informs the user that when a third-party component is updated, the updated version is inspected, and the risks are evaluated.Security
28The benefits and advantages of using the app are explained.Appropriateness and Suitability
29Experts have participated in the development of the app.Appropriateness and Suitability
30The app informs the user that it is based on scientific findings.Appropriateness and Suitability
31The app informs the user that it is developed in accordance with ethical principles and values.Appropriateness and Suitability
32The possible health risks for the user are identified.Safety
33The app complies with regulatory standards as a medical device.Safety
34The user is warned when adverse events are identified.Safety
35The app recommends that users always consult a specialist if they have questions, or it warns users that the app is not meant to replace the services provided by a health professional.Safety
36The app works correctly.Technology Performance
37Functions are correctly retrieved after events external to the app occur.Technology Performance
38The app uses mobile device resources efficiently (eg, battery, CPU, memory, data, network, etc), giving it a level of performance high enough not to interfere with the user’s experience.Technology Performance
39The app has a data recovery system in case of loss.Technology Performance

Overview

The results are organized according to the 3 research questions and the corresponding methodological components of the study. We first describe the mobile health apps identified through organizational recommendations and the scientific literature. We then summarize the empirical evidence available for these apps, including an assessment of the risk of bias and quality of these studies. Finally, we present the exploratory accessibility and functionality appraisal and the app quality assessment of the identified apps.

Mobile Health Apps Identified Through Organizational Recommendations

After combining and deduplicating apps identified through organizational recommendations and the scientific literature, 19 unique mobile health apps were included in the review. Fifteen apps were identified through organizational recommendations and 11 were evaluated in the empirical studies included in the qualitative synthesis. These counts should not be summed because 7 apps were identified through both sources, 8 were identified only through organizational recommendations, and 4 were identified only through empirical studies. Apps were counted as unique when they represented distinct apps after comparison by app name, developer, intended function, and platform availability. Among the 15 apps identified through organizational recommendations, all were freely available, and most (14/15, 93%) were compatible with both iOS and Android platforms. Across the 19 unique apps included in the review, none specifically targeted psychological functioning or mental health concerns. Six apps (ie, Medisafe, MyFitnessPal, SACYL Cita Previa, Salud Informa, SCSalud, and SESCAM) were recommended by both Fundación ONCE and the American Foundation for the Blind, whereas the remaining apps were endorsed by a single organization.

Apps identified only through the scientific literature were retained as additional unique apps when they represented distinct mobile apps not already captured through organizational recommendations. Across the 15 apps identified through organizational recommendations, 2 broad functional categories were identified. First, several apps supported health self-management or health-related information access, including medication scheduling, medication information retrieval, glucose monitoring, nutrition tracking, or physical activity support. These included apps with medication scheduling and reminders (eg, Medisafe and Alarma de Medicamentos), medication information access or voice-based output (eg, ScripTalk and Medicamento Accesible Plus), glucose monitoring or diabetes self-management functions (eg, Glucose Buddy Diabetes Tracker, OneTouch Reveal, DiabetesPal, and FreeStyle LibreLink), and nutrition or weight management support (eg, MyFitnessPal). Second, several apps primarily supported health care access or administrative functions, such as appointment scheduling, prescription management, or integration with regional public health systems (eg, SACYL Cita Previa, Salud Informa, SCSalud, SESCAM, GVA + Salut and Astursalud Cita Previa). These apps are linked to specific Spanish regional public health systems and are generally restricted to individuals receiving care within those systems. They are therefore not broadly available or directly transferable to users in other national or regional health care contexts. These administrative apps were explicitly identified through the organizational recommendation component and may provide meaningful access to appointments, prescriptions, health records, and other services within their intended local settings. However, they should be interpreted as a separate category of locally contextualized health care access tools rather than as equivalent to internationally available clinical self-management apps, such as medication management, glucose monitoring, or health information tools. The main features and functional categories of these apps are summarized in Table 2.

Table 2. Main features of mobile health apps identified through organizational recommendations for individuals who are blind or have low vision.
Mobile appFunctional categoryaOrganizationOperating systemDeveloperLanguagesKey featuresPriceDownloads, n
Alarma de MedicamentosMedication managementFundación ONCEAndroid/iOSAplicativos legais LTDA-MEEnglish, Spanish, Portuguese, French, German, Italian, Russian, Korean, Turkish, and othersCustomizable medication reminders and dosage trackingFree with in-app purchases>1 million
Astursalud Cita PreviaHealth care access or administrativeFundación ONCEAndroidGobierno del Principado de AsturiasSpanishManage primary care appointments within the Asturias (Spain) regional public health systemFree76,000
DiabetesPalDiabetes self-managementAmerican Foundation for the BlindAndroid/iOSPascal FreiburghausEnglish and GermanDiabetes management: track glucose, insulin, and meals; sync across devices via iCloud, Dropbox, or WebDAVFree to download with in-app purchases>50,000 (Android)
FreeStyle LibreLinkGlucose monitoringFundación ONCEAndroid/iOSAbbott Diabetes Care IncMultilingual (includes English, Spanish, French, Italian, and more)Glucose monitoring with sensor technology; provides historical trends; compatible with LibreView platformFree to download with in-app purchases>1 million
Glucose Buddy Diabetes TrackerDiabetes self-managementAmerican Foundation for the BlindAndroid/iOSAzumio IncEnglishLogs blood glucose, meals, and medications; integrates with Apple Health and Dexcom devices; provides detailed reports and optional coachingFree with in-app purchases>1 million
GVA + SalutHealth care access or administrativeFundación ONCEAndroid/iOSGeneralitat ValencianaSpanish and Catalan from ValènciaAppointment scheduling, medical records, prescriptions, telemedicine, and access to services within the Valencian (Spain) regional public health systemFree2.4 million
Medicamento Accesible PlusMedication information accessFundación ONCEAndroid/iOSILUNION Accesibilidad, Fundación ONCE, Fundación Vodafone España, and Consejo General de Colegios Farmacéuticos.SpanishAccessible medication information (indications, dosage, and warnings); includes food intolerance, pregnancy safety, and doping riskFree>50,000 (Android)
MedisafeMedication managementAmerican Foundation for the Blind/ONCEAndroid/iOSMedisafe IncAvailable in multiple languages, including English, Spanish, French, German, and morePill reminders and medication scheduling, drug interaction alerts,
appointment tracking, and MedFriend caregiver support
Free with in-app purchases>10 million (Android)
MyFitnessPalNutrition or weight managementAmerican Foundation for the Blind/ONCEAndroid/iOSMyFitnessPal IncEnglish and additional languages for localized versionsFood and nutrition tracking, barcode scanner, and macro- and micronutrient analysisFree with optional in-app purchases for premium features>200 million (worldwide)
OneTouch RevealGlucose monitoringAmerican Foundation for the BlindAndroid/iOSLifeScan IncEnglish, French, German, Italian, Spanish, Portuguese, Dutch, Czech, Japanese, Slovenian, Polish, and VietnameseTracks blood sugar readings via integration with OneTouch Verio Reflect and Verio Flex meters, allows manual data entry, and provides visual summaries, cloud synchronization, and web integrationFree>1 million
SACYL Cita PreviaHealth care access or administrativeAmerican Foundation for the Blind/ONCEAndroid/iOSJunta de Castilla y LeónSpanishManage, book, consult, and cancel appointments at health centers within the Castilla y León region (Spain); locate health centers; and manage multiple health cardsFree>1 million
Salud InformaHealth care access or administrativeAmerican Foundation for the Blind/ONCEAndroid/iOSGobierno de AragónSpanishManage medical appointments, view treatment sheets, receive notifications, and manage health cards within the Aragón (Spain) regional public health systemFreeNo data
SCSaludHealth care access or administrativeAmerican Foundation for the Blind/ONCEAndroid/iOSGobierno de CanariasSpanishAppointment management, medical record consultation, and health card information within the Canary Islands (Spain) regional public health systemFree>500,000
SESCAMHealth care access or administrativeAmerican Foundation for the Blind/ONCEAndroid/iOSCastilla-La Mancha Health ServiceSpanishManage medical appointments, access health reports, and use personalized services within the Castilla-La Mancha (Spain) regional public health systemFree>100,000
ScripTalkMedication information accessWorld Blind UnionAndroid/iOSEn-Vision America IncAfrikaans, German, Amharic, Armenian, Bengali, Burmese, Bulgarian, Cambodian, Catalan, Czech, Chinese, Korean, Croatian, Danish, Slovak, Slovenian, Estonian, Filipino, Finnish, French, Greek, Haitian, Hebrew, Hindi, Hungarian, Indonesian, English, Italian, Japanese, Laotian, Latvian, Lithuanian, Malay, Marathi, Dutch, Nepali, Norwegian Bokmal, Pashto, Persian, Polish, Portuguese, Romanian, Russian, Serbian, Somali, Spanish, Swahili, Swedish, Thai, Turkish, Ukrainian, Vietnamese, and ArabicAudio descriptions of prescription labels via RFIDb technology; reads drug name, dosage, and warningsFree>1000 (Android; no data for iOS)

aFunctional categories distinguish apps primarily intended for health self-management or health-related information access from apps primarily intended to support health care access or administrative functions.

bRFID: radio frequency identification.

Studies on Health-Related Apps in Scientific Databases

The database search was conducted in 2 phases. The initial search covered records published through December 2025 in ScienceDirect, PubMed or MEDLINE, and other NCBI resources. In April 2026, the search was updated across these 3 databases and expanded to include Scopus, Web of Science, and the ACM Digital Library; all 6 databases were searched from inception through April 2026. Across these database searches, 163 records were identified. In addition, 3 papers were identified through manual reference screening, yielding a total of 166 records. After removing 17 duplicates, 149 titles and abstracts of papers were screened. Of these, 101 were excluded, leaving 48 papers for full-text review. Following eligibility assessment, 14 studies were included in the qualitative synthesis.

An additional expanded search was also conducted across 6 databases to further examine the coverage of the search strategy: ScienceDirect, PubMed or MEDLINE, PubMed Central, Scopus, Web of Science, and the ACM Digital Library. This expanded search retrieved 1371 records: ScienceDirect (n=222), PubMed or MEDLINE (n=22), PubMed Central (n=54), Scopus (n=579), Web of Science (n=158), and ACM Digital Library (n=336). After duplicate removal and initial screening, 40 papers were selected for further review. Four papers underwent full-text eligibility assessment; however, none met the inclusion criteria. Therefore, the expanded search did not change the final number of included studies. Figure 1 presents the PRISMA flow diagram illustrating the paper selection process.

‎
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart illustrating the main study selection process for health-related mobile apps targeting individuals who are blind or have low vision.

The 14 empirical studies examined 11 different mobile health apps identified as relevant to individuals who are blind or have low vision, most often in the context of medication management, diabetes, hypertension, nutrition, or physical activity. However, the population focus of the evidence varied. Some studies specifically involved participants who were blind or had low vision, whereas others evaluated apps recommended for, or potentially relevant to, blind and low-vision users but were conducted in broader clinical or general populations where visual impairment status was not reported. Not all apps recommended by organizations had corresponding scientific evidence, and conversely, not all apps identified in the scientific literature were endorsed by organizations.

These studies used a range of methodologies: cross-sectional designs (6/14, 42%), observational studies (6/14, 42%), and randomized clinical trials (2/14, 14%). Most studies were conducted in the United States (6/14, 42%). Table 3 provides an overview of the 14 studies and the 11 apps evaluated. Because the included studies differed substantially in population focus and outcome type, Table 3 distinguishes between studies involving blind or low-vision participants and studies conducted in broader clinical or general populations where visual impairment status was not reported, and between studies evaluating objective or clinical outcomes and those focused primarily on usability, feasibility, satisfaction, or accessibility-related outcomes. Most of the identified apps were developed specifically to support medication management and access to pharmaceutical information. Despite geographic diversity, several core features were common: (1) voice output for medication identification and instructions; (2) barcode or Global Trade Item Number scanning to recognize medication packaging; (3) accessible search interfaces, usable by text, voice, or image; and (4) reminder systems for dosing and medication refills. These apps were primarily developed for Android platforms and followed user-centered design principles. Many included adjustable user interfaces (eg, text size, spoken descriptions, and voice navigation). Overall, the evidence was heterogeneous in both population focus and outcome type. Studies involving blind or low-vision participants primarily reported findings related to usability, feasibility, medication information access, perceived autonomy, or satisfaction with apps such as ScripTalk, MyPills, FarmaceuticApp, and Ru Tan Ya [5,44,45]. Studies conducted in broader clinical or general populations reported more objective or large-scale outcomes, including medication adherence and blood pressure control for Medisafe [5,46], glycemic metrics for FreeStyle LibreLink [47] and OneTouch Reveal [48,49], weight management behavior for MyFitnessPal [50], and dietary assessment accuracy for MyFitnessPal [51]. However, findings from broader populations should be interpreted as indirectly relevant to blind and low-vision users unless visual impairment status was specifically assessed. In addition, some barriers were noted. For example, the study of Medicamento Accesible Plus highlighted low digital literacy among older adults as a barrier to effective app use [52].

Table 3. Overview of empirical studies identified on mobile health apps identified as relevant to individuals who are blind or have low vision by population relevance and outcome type in chronological order of publication.
Authors (year), countryPurposes of the studyAppsPrincipal functionsPopulation relevance to blind or low-vision usersaLanguagesSample of studyType of studyTechnical characteristicsOutcome typeResults
Spektor et al (2015) [53],
United States
Evaluate effectiveness of ScripTalk for reading prescription labelsScripTalkReads prescription labels aloudDirect evidence: BLVb-specific sampleEnglish12 veterans with visual impairmentsField studyAllows iOS devices with Near Field Communication capability to read ScripTalk Talking Labels.Medication access and adherence-related outcomeImproved treatment adherence and independence in medication use
Bee et al (2016) [54],
Singapore
To evaluate the app for insulin use in insulin-naive patients with type 2 diabetesDiabetesPalInsulin adjustment based on glycemic goalsIndirect evidence: broader clinical population; BLV status not reportedEnglish62 participants (32 intervention, 30 control); type 2 adult patients with diabetesPilot randomized clinical trialDiabetes data recording (eg, glucose, insulin, medication, blood pressure, etc);
graph generation
Insulin titration feasibility and safetySafe and feasible for insulin titration;
no severe hypoglycemia recorded
Morawski et al (2018) [46],
United States
To evaluate Medisafe’s impact on antihypertensive adherence and blood pressure controlMedisafeMedication reminders, adherence reports, and caregiver supportIndirect evidence: broader clinical population; BLV status not reported17 languages, including Spanish, English, Arabic, Danish, Dutch, Finnish, French, German, Hebrew, Italian, Japanese, Korean, Portuguese, Russian, Simplified Chinese, and Turkish412 adults with uncontrolled hypertensionRandomized clinical trialAdherence tracking;
MedFriend support;
multicondition tracking
Medication adherence and blood pressure controlImproved adherence significantly compared with the control group
González Oñate et al (2018) [52],
Spain
Evaluate accessibility of medication information for older adultsMedicamento Accesible PlusSearch and read medicine informationIndirect evidence: general older adult population; BLV status not reportedSpanishOlder adults in SpainDescriptive studyBarcode scanning;
health database access
Accessibility and digital literacyIdentified digital divide, highlighting the need for promoting digital literacy
Gordon et al (2019) [55], United StatesTo analyze weight loss goal setting on MyFitnessPalMyFitnessPalDiet and exercise tracking toolIndirect evidence: general app-user population; BLV status not reported23 languages, including Spanish, English, French, German, Italian, Portuguese, Swedish,
Danish, Norwegian, Bokmal, Dutch, Russian, Korean, Japanese Simplified, Chinese Traditional, Chinese Filipino, Indonesian, Malay, Polish, and Turkish
1.4 million usersObservational studyMeal planning;
activity tracking;
goal customization
Weight management behaviorEffective tool for behavioral change; consistent users had better weight loss outcomes
Nedovic et al (2019) [44],
Switzerland
To examine how the app can support medication management for blind and visually impaired peopleMyPillsIdentification of medication packages, voice output of drug name and intake instructions, and voice output of package insertsMixed evidence: sample included blind participants and sighted participantsDifferent languages (not specified)Two blind and 4 sighted individuals (aged 30‐70 years)Cross-sectional studyReminders for drug intake and reordering;
audio access to package inserts;
RFIDc scanning with GTINd support
Usability and medication management supportUsers quickly understood the app;
blind users found package scanning useful
Shade et al (2019) [50],
United States
To explore usability and usefulness of Medisafe among older adults living in rural communitiesMedisafeMedication remindersIndirect evidence: general older adult population; BLV status not reported17 languages, including Spanish, English, Arabic, Danish, Dutch, Finnish, French, German, Hebrew, Italian, Japanese, Korean, Portuguese, Russian, Simplified Chinese, and Turkish13 older adults residing in rural communitiesFeasibility studyAdherence tracking;
MedFriend support;
multicondition tracking
Usability, usefulness, and feasibilityNo usability issues, useful for medication tracking and adherence
Madrigal-Cadavid et al (2020) [5],
Colombia
To design and develop a mobile drug information app for individuals with visual disabilitiesFarmaceuticAppMedication search (barcode, voice, or text command), access medication information, and nearby pharmacies/hospitals locatorDirect evidence: BLV-specific sampleSpanish48 participants with visual disabilities (age range: 18‐60 years)Cross-sectional descriptive studyVoice descriptions;
scalable fonts;
configurable accessibility settings;
counterfeit detection;
prescription history
User satisfaction and perceived usefulnessRated 4 to 5 on a 1 to 5 numerical rating scale;
all participants stated they would use it for medication adherence
Nimmolrat et al (2021) [45],
Thailand
To analyze, design, and develop a pharmaceutical app for users with visual impairment and test usabilityRu Tan YaSearch medicinal information, timer, map to pharmacies, medication historyDirect evidence: BLV-specific sampleThai60 volunteersExperimental studyTouch screen;
voice user interface design;
slide rule and navigation techniques functions;
optimized text or image access
Usability and satisfactionUsability was low but most users were satisfied
Kao et al (2022) [56],
United States
To evaluate glucose monitoring effectiveness using the appFreeStyle LibreLinkBlood glucose monitoring and trend analysisIndirect evidence: broader diabetes population; BLV status not reportedEnglish14,000 FreeStyle Libre users;
patients with type 1 and 2 diabetes
Observational studyHistory view;
blood glucose alarms;
diet, insulin use, and exercise tracking;
share data with doctor
Glucose metricsStatistically significant improvements in blood glucose metrics compared with traditional reader users
Grady et al (2023) [47],
United States– United Kingdom
To evaluate Bluetooth meter (OneTouch Verio Reflect) together with a mobile app (OneTouch Reveal) for diabetes controlOneTouch RevealGlucose monitoring,
trend alerts, health data logging
Indirect evidence: broader diabetes population; BLV status not reported12 languages, including Spanish, German, Czech, Slovenian, French, English, Italian, Japanese, Dutch, Polish, Portuguese, and Vietnamese55,000 users;
patients with type 1 and 2 diabetes
Retrospective observational studyPattern detection;
step tracking;
glucose reports
Glycemic outcomesStatistically significant improvements in glycemia: fewer highs or lows; better average blood glucose levels
Merino et al (2023) [48],
different countries
To evaluate OneTouch Reveal (OTR Pro) for remote diabetes management during the COVID-19 pandemicOneTouch RevealMonitoring glucose levels, reminders, track health dataIndirect evidence: broader diabetes population; BLV status not reported12 languages, including Spanish, German, Czech, Slovenian, French, English, Italian, Japanese, Dutch, Polish, Portuguese, and Vietnamese1500 users during virtual consultationsDescriptive observational studyDetects blood glucose patterns;
tracks daily steps;
creates reports for therapeutic decisions
Clinical practice or diabetes management supportFacilitated clinical practice;
ease of secure data sharing;
enhanced therapeutic decisions
Banal et al (2024) [49],
Philippines
To evaluate validity and intercoder reliability of MyFitnessPal for dietary assessmentMyFitnessPalDiet and exercise tracking toolIndirect evidence: broader diabetes population; BLV status not reported21 languages, including Spanish, English, French, German, Italian, Portuguese, Swedish, Danish, Norwegian, Bokmal, Dutch, Russian, Korean, Japanese Simplified, Chinese
Traditional, Chinese Filipino, Indonesian, Malay, Polish, and Turkish
37 Filipino adults with obesityObservational studyMeal planning;
activity tracking;
dietary intake estimations
Dietary assessment validity and reliabilityUseful for diet tracking; some limitations in nutritional estimate accuracy
Choi et al (2025) [51],
United States
Develop an accessible conversational mHealth app (Personalized and Conversational
Health Agent) to support physical activity in blind and low-vision individuals
Personalized and Conversational Health AgentPersonalized and Conversational
Health Agent
is a conversational, voice-based health assistant that provides personalized recommendations for physical activity, enables self-monitoring of health metrics (steps and heart rate), and facilitates interactive communication via a voice user interface
Direct evidence: BLV-specific expert evaluationEnglish with voice-based natural language interaction (ie, via a conversational agent using a large language model)Two blind accessibility experts evaluated the prototypeDesign and development study with qualitative expert evaluationUses iOS with large language model integration;
voice user interface;
multimodal feedback (audio and haptic via Apple Watch);
uses physical activity assessment and activity guidelines for Americans to provide physical activity recommendations via an algorithm
Prototype accessibility and expert evaluationSuccessful development of a functional prototype with accessible user interface, effective voice interaction, and multimodal feedback;
includes 2 experts to test the prototype;
limitations identified included response latency, a lack of personalized physical activity feedback, and the need for clearer goal-setting explanations

a“Direct evidence” refers to studies that specifically included blind or low-vision participants or expert evaluators. “Mixed evidence” refers to studies including both blind or low-vision and sighted participants. “Indirect evidence” refers to studies evaluating apps identified as relevant to blind or low-vision users but conducted in broader clinical or general populations where visual impairment status was not reported.

bBLV: blind or low vision.

cRFID: radio frequency identification.

dGTIN: Global Trade Item Number.

Assessment of Bias and Quality of Evidence

The interrater reliability in the assessment of methodological quality was high, with 98% agreement between reviewers across all included studies. This high level of agreement reflects the use of a structured appraisal framework with clearly defined criteria, as well as prior calibration between reviewers before the formal assessment. Minor discrepancies, mainly due to different interpretations of the criteria, were resolved through discussion, without the need to involve a third reviewer. A considerable proportion of the studies included in the review presented a moderate or high risk of bias, and out of 14 studies, only 6 (42%) met the criteria for good methodological quality: DiabetesPal [49,54,55], Medisafe [52], MyFitnessPal [50,51], FreeStyle LibreLink [47], and OneTouch Reveal [48]. Most papers reported a clear objective, defined population, and inclusion and exclusion criteria [47,48,56]. However, many did not report participation rates or whether assessors were blinded [45,52]. Table 4 provides a summary of this information. Table 4 should be interpreted as a structured overview of methodological quality across NIH criteria. The overall quality rating reflects the number of criteria met, whereas “Cannot determine” indicates insufficient information to judge an item and “Not applicable” indicates that the criterion was not relevant to the study design.

Table 4. Methodological quality of studies—the National Institutes of Health Quality Assessment Toola.
Authors (year)1234567891011121314Quality ratingb
Banal et al (2024) [49]YesYesYesYesYesYesYesYesYesYesYesYesYesYesGood
Bee et al (2016) [54]YesYesCDcYesYesYesYesYesYesYesYesCDYesCDGood
Choi et al (2025) [51]YesYesNAdYesYesNANANACDNACDNANANAPoor
González Oñate and Fanjul Peyró (2018) [52]YesYesNoYesYesYesYesYesYesYesYesNoNANoFair
Gordon et al (2019) [55]YesYesYesYesYesYesYesYesYesYesYesYesYesYesGood
Grady et al (2023) [47]YesYesCDYesYesYesYesYesYesYesYesCDYesCDGood
Kao et al (2022) [56]YesYesYesYesYesYesYesYesYesYesYesNAYesYesGood
Madrigal-Cadavid et al (2020) [5]YesYesYesYesYesNANANAYesNAYesCDNANAFair
Merino et al (2023) [48]YesYesCDYesYesYesYesYesYesYesYesCDCDCDFair
Morawski et al (2018) [46]YesYesYesYesYesYesYesYesYesYesYesNoYesYesGood
Nedovic et al (2019) [44]YesYesCDYesNoNANANAYesNAYesNoYesNoPoor
Nimmolrat et al (2021) [45]YesYesCDYesYesNANANAYesNAYesCDNANAPoor
Shade et al (2019) [50]YesYesNoYesYesYesYesYesYesNoYesNoYesNoFair
Spektor et al (2015) [53]YesYesCDYesYesYesYesYesYesYesYesNoNACDFair

aThese items are as follows: 1=study objectives stated, 2=study population defined, 3=eligible participation rate (at least 50%), 4=participant selection and inclusion and exclusion criteria uniformity, 5=sample size sufficient and/or described, 6=exposure measured prior to outcome, 7=sufficient time frame for association between exposure and outcome, 8=inclusion exposure level, 9=exposure measures valid and reliable, 10=multiple exposure measurements, 11=outcome measures valid and reliable, 12=outcome assessors blinded, 13=Loss to follow-up postbaseline (20% or less), and 14=confounders measured and adjusted between exposure and outcome.

bQuality ratings were derived using the National Institutes of Health Quality Assessment Tool. Overall ratings were based on the total number of criteria met: poor=0‐6 “Yes” responses, fair=7‐10 “Yes” responses, and good=11‐14 “Yes” responses.

cCD: cannot determine (insufficient information available to judge the criterion).

dNA: not applicable (criterion not relevant to the study design).

Accessibility, Functionality, and Quality of the Identified Mobile Apps

We conducted an exploratory user-informed accessibility appraisal of the identified apps using the WCAG 2.1 principles: Perceivable, Operable, Understandable, and Robust. These ratings should be interpreted as illustrative user-informed observations rather than as formal accessibility certification, psychometric assessment, or standardized measurement outcomes. The appraisal suggested variability in accessibility across the apps. Within this exploratory user-informed appraisal, MyPills received the most favorable accessibility profile, obtaining “High” ratings across all 4 WCAG 2.1 [43] principles. Participants highlighted its compatibility with screen readers, clear instructions, and reliable performance across devices. In contrast, 6 apps (ie, Astursalud Cita Previa, Glucose Buddy Diabetes Tracker, SESCAM, SCSalud, SACYL Cita Previa, and MyFitnessPal) received “Low” ratings on most or all WCAG principles within this exploratory appraisal. Common issues included poor support for assistive technologies, visually cluttered interfaces without alternatives, and navigation challenges for screen reader users. Examples of accessibility barriers identified during the appraisal included unlabeled controls, insufficient clarity of instructions, inconsistent navigation flows, and limited compatibility with screen-reader interaction. Conversely, apps with clearer menu structures, accessible labeling, and more predictable navigation were judged more favorably. Of the mobile apps identified, 2 (ie, FarmaceuticApp and Ru Tan Ya) could not be downloaded or assessed because they were not available for download in the app stores at the time of assessment. Accessibility ratings of the remaining apps are summarized in Table 5.

Table 5. Exploratory user-informed accessibility appraisal of mobile apps for users who are blind or have low vision based on the WCAGa 2.1 principlesb.
Name of appPrinciple 1: PerceivablePrinciple 2: OperablePrinciple 3: UnderstandablePrinciple 4: Robust
Alarma de MedicamentosHighHighHighModerate
Astursalud Cita PreviaLowLowLowLow
DiabetesPalModerateModerateModerateLow
FreeStyle LibreLinkModerateModerateModerateLow
Glucose Buddy Diabetes TrackerLowModerateLowLow
GVA + SalutModerateModerateModerateLow
Medicamento Accesible PlusModerateModerateModerateLow
MedisafeHighHighHighModerate
MyFitnessPalLowModerateLowLow
MyPillsHighHighHighHigh
OneTouch RevealModerateHighModerateModerate
Personalized conversational health agentHighModerateModerateLow
SACYL Cita PreviaLowLowLowLow
Salud InformaModerateLowModerateLow
SCSaludLowLowLowLow
SESCAMLowLowLowLow
ScripTalkHighHighHighModerate

aWCAG: Web Content Accessibility Guidelines.

bRatings were derived from an exploratory user-informed appraisal involving 4 participants (2 blind and 2 with low vision) and should not be interpreted as formal accessibility certification, psychometric assessment, or standardized measurement outcomes.

App quality was assessed using the MAG [34], which includes 39 criteria covering usability, privacy, security, safety, appropriateness, and technology performance. The appraisal showed substantial variability across apps. Medisafe scored highest, meeting 34 of 39 criteria, whereas SACYL Cita Previa scored lowest, meeting 8 of the 39 criteria. Table 6 presents a summary of the MAG total score and the descriptive score band assigned to each app for this review. Higher total scores indicate that a greater number of quality criteria were met, whereas lower scores reflect more limited compliance across MAG domains. The complete item-level MAG appraisal is provided in Multimedia Appendix 4.

Table 6. Summary of app-quality appraisal using the Mobile App Development and Assessment Guide (MAG).
AppMAG total score of 39, naDescriptive MAG-based interpretationb
Medisafe34Higher app quality
Medicamento Accesible Plus33Higher app quality
ScripTalk32Higher app quality
OneTouch Reveal31Higher app quality
FreeStyle LibreLink29Higher app quality
Glucose Buddy Diabetes Tracker29Higher app quality
MyFitnessPal28Higher app quality
MyPills27Higher app quality
Salud Informa25Moderate app quality
DiabetesPal24Moderate app quality
GVA + Salut22Moderate app quality
SCSalud18Lower app quality
SESCAM18Lower app quality
Astursalud Cita Previa16Lower app quality
Alarma de Medicamentos13Lower app quality
Personalized Conversational Health Agent12Lower app quality
SACYL Cita Previa8/39Lower app quality

aThe MAG includes 39 criteria. Higher scores indicate that a greater number of app-quality criteria were met.

bDescriptive score bands were created for this review because the MAG does not provide predefined cutoff points for interpreting total scores: higher app quality ≥27/39 criteria met, moderate app quality 20-26/39 criteria met, and lower app quality ≤19/39 criteria met. These categories were used only to aid interpretation of the descriptive MAG scores and should not be interpreted as validated MAG thresholds. The full item-level MAG appraisal is provided in Multimedia Appendix 4.


Principal Findings

This systematic review examined the current landscape of mobile health apps intended to support the physical and psychological functioning of individuals who are blind or have low vision. Overall, the findings suggest that this field remains limited in scope, uneven in accessibility and quality, and only partially supported by empirical evidence.

Three main findings emerged. First, the number of identified apps was small, and only a subset had been evaluated in peer-reviewed studies. Second, the available apps focused primarily on physical functioning, particularly medication management and health data tracking, whereas no apps specifically targeting psychological functioning were identified. Third, accessibility and app quality varied considerably, with only a small number of apps performing well across both WCAG and MAG criteria. These findings are broadly consistent with a recent systematic review on the usability of mobile apps for individuals with visual impairments [29]. Although that review did not focus specifically on health-related apps or on physical and psychological functioning, it similarly concluded that the usability of mobile apps for visually impaired users remains limited due to device-related barriers (eg, camera-based interfaces) and user interaction challenges (eg, difficulties interpreting graphical user interfaces) [29].

With respect to the first research question, the apps identified through organizational recommendations, and the systematic search of scientific literature reflected a relatively narrow functional landscape. Most supported medication use, medication information access, glucose monitoring, nutrition tracking, or physical activity support. A separate subset of apps primarily supported health care access or administrative functions, such as appointment scheduling, prescription management, or access to regional health system information. These latter tools may be useful for navigating health care services, particularly in local contexts, but they are functionally distinct from clinical self-management apps such as medication management, glucose monitoring, nutrition tracking, or physical activity tools. Overall, the identified apps represent a restricted subset of the possible ways in which mobile health apps might support functioning in individuals who are blind or have low vision. As a result, they do not reflect a broader conceptualization of functioning that includes psychological well-being, self-efficacy, autonomy, and participation in daily life.

Importantly, the characterization of this landscape as limited should not be understood as a simple consequence of the number of apps identified or of the inclusion of geographically restricted administrative tools. Rather, it reflects the narrow range of functions addressed across the identified apps, the limited number supported by population-specific empirical evidence, the variability observed in accessibility and app quality, and the absence of apps primarily addressing psychological functioning.

A particularly important finding was the absence of apps specifically targeting psychological functioning. This should be interpreted cautiously, as it reflects an absence of identified apps rather than definitive evidence that none exists. Some apps may include psychological or mental health–related components; however, within the scope of this review, we did not identify apps primarily designed for, or empirically evaluated in, blind and low-vision populations with a specific focus on psychological or mental health functioning. Nonetheless, this gap is clinically meaningful given the elevated burden of depression, anxiety, and psychological distress in individuals who are blind or have low vision [19]. This observation is consistent with Inal and colleagues [57], who reviewed 42 usability studies of mobile mental health technologies and found that none included users with visual impairments. Taken together, these findings suggest that psychological functioning remains insufficiently addressed in both app development and research for this population. By contrast, app-based interventions addressing pain-related symptoms and quality of life have been developed for other chronic pain populations. For example, Fibroline incorporates a self-administered cognitive behavioral intervention designed for young people with fibromyalgia or chronic widespread pain, illustrating how psychological and symptom management components can be integrated into a mobile health app outside the context of blindness and low vision [24,58].

With respect to the second research question, the empirical evidence base was limited in both size and scope. In this review, “evidence” refers to the existence of empirical studies examining an app and should not be interpreted as formal validation in a psychometric, regulatory, or certification sense. Only a minority of identified apps had been examined in empirical studies, and the methodological quality of those studies was variable. Importantly, the available evidence differed in its relevance to blind and low-vision users and in the type of outcomes assessed. Some studies directly involved participants who were blind or had low vision, whereas others evaluated apps recommended for this population but did so in broader clinical or general populations where visual impairment status was not reported. Therefore, evidence of effectiveness or usability in general populations should be interpreted as indirectly relevant rather than as population-specific evidence for blind and low-vision users. Importantly, the available evidence also differed according to the type of outcomes that were assessed. Some studies reported objective or clinical outcomes, including medication adherence and blood pressure control, glucose metrics, weight management behavior, or dietary assessment accuracy. Other studies focused primarily on usability, feasibility, acceptability, satisfaction, medication information access, or perceived usefulness. Consequently, the current evidence base is better understood as comprising 2 complementary forms of evidence: studies evaluating objective or clinical outcomes, predominantly conducted in broader populations, and studies examining usability, accessibility, or user experience, more commonly conducted with participants who were blind or had low vision. This distinction is important because the existence of an empirical study does not necessarily imply demonstrated clinical effectiveness, and findings from broader populations should not be interpreted as direct evidence of effectiveness, accessibility, or usability for blind and low-vision users. Studies conducted in broader clinical or general populations examined objective or clinical outcomes for Medisafe [46], including medication adherence and blood pressure control; FreeStyle LibreLink [56] and OneTouch Reveal [47,48], including glycemic metrics; and MyFitnessPal [49,55], including weight management behavior and dietary assessment accuracy. By contrast, studies involving blind or low-vision participants more commonly examined usability, feasibility, medication information access, satisfaction, perceived autonomy, or prototype accessibility for apps such as ScripTalk [53], MyPills [44], FarmaceuticApp [5], Ru Tan Ya [45], and PCHA [51]. Accordingly, the literature provides some evidence of clinical or behavioral benefit for selected apps in broader populations and some direct evidence of usability or perceived value among blind or low-vision users but very limited evidence combining population-specific evaluation with objective health-related outcomes. The review also identified only partial overlap between apps recommended by organizations and apps supported by empirical evidence. That is to say, several apps endorsed by organizations lacked corresponding scientific evaluation, whereas some apps described in the literature were not recommended by organizations. This discrepancy is important because organizational recommendations may shape what users, families, and clinicians perceive as credible or useful. The findings therefore highlight the need for closer alignment between research, practice, and dissemination processes so that recommended tools are not only accessible but also supported by evidence.

With respect to the third research question, accessibility and app quality were inconsistent across the identified apps. Only a small number of apps appeared to perform well across the exploratory WCAG-informed appraisal and the MAG assessment, whereas others showed substantial limitations. In the exploratory user-informed appraisal, some apps endorsed by organizations appeared to present potential accessibility barriers, including unlabeled graphical elements, limited screen reader compatibility, and complex navigation structures. These observations should be interpreted cautiously because they were derived from a small exploratory appraisal rather than from a formal accessibility validation study. Nevertheless, they are consistent with previous work in accessibility, human-computer interaction, and assistive technology, which has highlighted persistent problems related to interface complexity, visually dependent interaction models, and inadequate compatibility with assistive tools [29,59-61]. Our findings extend that literature by showing that these barriers remain highly relevant even in apps with apparent health value or organizational endorsement.

The user-informed accessibility appraisal also suggests that technical accessibility alone may not be sufficient to ensure meaningful use. Even when apps were theoretically compatible with assistive features, their practical value could still be limited by poor onboarding, inadequate support, unfamiliar interaction patterns, or broader digital literacy barriers. Accessibility, therefore, should not be understood solely as technical compliance but also as the extent to which an app can be used effectively in real-world contexts by its intended users.

At the same time, some apps demonstrated comparatively strong accessibility and overall quality. For example, within the exploratory WCAG-informed appraisal, MyPills received the most favorable accessibility profile, obtaining “High” ratings across all 4 WCAG principles, whereas Medisafe achieved the highest MAG score (34/39), suggesting particularly strong performance in broader app quality domains. More generally, the studies with the strongest designs reported improvements in medication outcomes, such as medication adherence, self-management, and user satisfaction. However, these findings should be interpreted cautiously, given the limited number of studies, their relatively small samples, and the generally high digital literacy of participants. By contrast, many other apps received low accessibility or quality ratings, and the methodological quality of the supporting studies was mixed overall. Several apps endorsed by organizations still showed substantial accessibility limitations across 1 or more WCAG domains and performed less well on the MAG appraisal. For example, despite being recommended by ONCE and the American Foundation for the Blind, MyFitnessPal relied heavily on visually structured content, complex menu hierarchies, and limited screen reader compatibility, which may reduce usability for individuals who are blind or have low vision. This illustrates a potentially important mismatch between organizational endorsement and real-world accessibility. More broadly, even apps that appeared technically accessible could still be difficult to use in practice because of limited onboarding, insufficient guidance, low awareness, and digital literacy barriers. Taken together, these findings suggest that technical accessibility alone is insufficient; effective dissemination, onboarding, and real-world usability are also essential to achieve meaningful impact.

These findings have several important implications. From a clinical perspective, they suggest that only a small number of apps currently offer reasonably credible and accessible tools for supporting physical functioning, particularly medication self-management. Clinicians may wish to be aware of these options but should also recognize that endorsement or availability does not necessarily imply accessibility, quality, or evidence of benefit. At the same time, the absence of identified apps targeting psychological functioning leaves an important gap in the digital support currently available for this population. From a development, policy, and research perspective, the findings point to the need for more rigorous and transparent standards for app development, evaluation, and recommendation. Apps intended for individuals who are blind or have low vision should be developed through participatory and inclusive co-design processes involving end users, clinicians, and accessibility specialists, and should be evaluated not only for intended usefulness but also for real-world accessibility and usability. This perspective is consistent with recent developments reflected in the WCAG 3.0 Working Draft [62]. Although this document is not a ratified standard, it illustrates an ongoing shift from a predominantly technical, criteria-based approach toward a more flexible framework centered on users’ diverse accessibility needs. In addition, future research should prioritize apps that address psychological functioning in ways that are both accessible and clinically meaningful and should include larger and more diverse samples, stronger study designs, and outcomes that extend beyond feasibility or satisfaction to capture meaningful indicators of functioning. Greater attention should also be given to accessible onboarding, guidance, and support features to facilitate sustained real-world use. Finally, future work should examine how emerging assistive and AI-enabled functionalities can be integrated into mobile health apps without increasing complexity or introducing new accessibility barriers.

Limitations

This review has several limitations that should be acknowledged. First, the identified studies were heterogeneous in design, geography, sample size, participant characteristics, and outcome measures, limiting comparability and precluding meta-analysis. In addition, although the present review included studies with qualitative and mixed methods components, it was not designed as a formal qualitative evidence synthesis. Applying frameworks such as those proposed in the Cochrane-Campbell Handbook for Qualitative Evidence Synthesis would entail a substantially different review design but may represent a valuable direction for future research focused on in-depth analysis of user experience and interaction design in this field. Second, restricting the search to English and Spanish publications may have excluded relevant studies in other languages, and despite a comprehensive search strategy, some studies may have been missed. In addition, some apps identified through the literature could not be directly assessed because they were not available for download at the time of review, which may introduce a degree of availability bias. Moreover, identifying apps through organizational recommendations may have introduced selection bias, as not all organizations publish or regularly update such recommendations. This process also introduced geographic and contextual limitations. Several organizationally identified apps were region-specific health care access or administrative tools linked to regional public health systems, which may limit their relevance to international readers and make them functionally distinct from clinical self-management apps. Therefore, the number and nature of identified apps should be interpreted in light of the sources consulted and the organizational recommendation process. Finally, the accessibility appraisal should be interpreted as a complementary and exploratory component intended to contextualize the review findings. It was not designed as a stand-alone usability study, formal accessibility validation, or psychometric assessment. Therefore, its findings should be understood as illustrative user-informed observations of potential accessibility barriers rather than as generalizable estimates of usability or definitive measurements of accessibility across the broader population of users who are blind or have low vision. However, its use is consistent with prior accessibility literature and with W3C guidance supporting the application of WCAG principles to mobile and nonweb software.

Despite the study’s limitations, this review shows that the mobile health apps identified through organizational recommendations and the scientific literature remain limited in scope, heterogeneous in function, uneven in accessibility and quality, and supported by a limited and heterogeneous empirical base. While a small number of apps appear promising, major gaps remain in accessibility, quality, and especially support for psychological functioning. Moving the field forward will require more than simply increasing the number of available apps. Future efforts should focus on developing apps that are accessible from the outset, rigorously evaluated, and developed in collaboration with the people they are designed to support.

Acknowledgments

No generative AI tools were used at any stage in the preparation of this manuscript.

Funding

This work was partly funded by grants from the Spanish Ministry of Economy, Industry and Competitiveness (RED2022-134869-T), the European Regional Development Fund (ERDF), and the Government of Catalonia (AGAUR; 2021SGR-730). ES is a Serra Húnter Fellow at the Department of Psychology, Universitat Rovira i Virgili, Catalonia, Spain. JM’s work is supported by ICREA-Acadèmia. The Chair in Pediatric Pain is supported by Fundación Grünenthal and ANUBIS.

Authors' Contributions

Conceptualization: JM (lead), CM (supporting)

Methodology: JM (lead), CM (supporting)

Investigation: CM (lead), JM (supporting), PLl-V (supporting)

Data curation: CM (lead), JM (supporting), PLl-V (supporting)

Writing – original draft: JM (lead), CM (supporting)

Writing – review & editing: JM (lead), CM (supporting), ES (supporting), PLl-V (supporting)

Supervision: JM (lead)

Project administration: JM (lead)

Conflicts of Interest

None declared.

Multimedia Appendix 1

Description of updated search.

DOCX File, 33 KB

Multimedia Appendix 2

Data extraction template.

DOCX File, 26 KB

Multimedia Appendix 3

Operationalization and scoring of Web Content Accessibility Guidelines (WCAG) 2.1 principles in the appraisal of mobile health apps.

DOCX File, 27 KB

Multimedia Appendix 4

Quality assessment of health-related mobile apps for individuals who are blind or have low vision, based on the Mobile App Development and Assessment Guide criteria.

DOCX File, 28 KB

Checklist 1

PRISMA checklist.

DOCX File, 32 KB

  1. World Health Organization. World Report on Vision. World Health Organization; 2019. ISBN: 978-92-4-151657-0
  2. Martínez-Pérez B, de la Torre-Díez I, López-Coronado M. Mobile health applications for the most prevalent conditions by the World Health Organization: review and analysis. J Med Internet Res. Jun 14, 2013;15(6):e120. [CrossRef] [Medline]
  3. Court H, McLean G, Guthrie B, Mercer SW, Smith DJ. Visual impairment is associated with physical and mental comorbidities in older adults: a cross-sectional study. BMC Med. Oct 17, 2014;12:181. [CrossRef] [Medline]
  4. Demmin DL, Silverstein SM. Visual impairment and mental health: unmet needs and treatment options. Clin Ophthalmol. 2020;14:4229-4251. [CrossRef] [Medline]
  5. Madrigal-Cadavid J, Amariles P, Pino-Marín D, Granados J, Giraldo N. Design and development of a mobile app of drug information for people with visual impairment. Res Social Adm Pharm. Jan 2020;16(1):62-67. [CrossRef] [Medline]
  6. Quinn TJ, Livingstone I, Weir A, et al. Accuracy and feasibility of an Android-based digital assessment tool for post stroke visual disorders-the StrokeVision app. Front Neurol. 2018;9:146. [CrossRef] [Medline]
  7. Mora C, Jensen MP, Miró J. Chronic pain in individuals who have visual impairments: a systematic review. J Vis Impair Blind. Mar 2026;120(2):117-133. [CrossRef]
  8. Coleman AL, Cummings SR, Ensrud KE, et al. Visual field loss and risk of fractures in older women. J Am Geriatr Soc. Oct 2009;57(10):1825-1832. [CrossRef] [Medline]
  9. Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ. Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. Nov 1, 2014;55(11):7589. [CrossRef]
  10. Kuang TM, Tsai SY, Hsu WM, Cheng CY, Liu JH, Chou P. Visual impairment and falls in the elderly: the Shihpai Eye Study. J Chin Med Assoc. Sep 2008;71(9):467-472. [CrossRef] [Medline]
  11. Zhang X, Bullard KM, Cotch MF, et al. Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol. May 2013;131(5):573-581. [CrossRef] [Medline]
  12. Lam BL, Christ SL, Lee DJ, Zheng DD, Arheart KL. Reported visual impairment and risk of suicide: the 1986-1996 national health interview surveys. Arch Ophthalmol. Jul 2008;126(7):975-980. [CrossRef] [Medline]
  13. Palbo A, Roed Rasmussen ML, Hansen MS, Subhi Y. Association between visual impairment and suicide: a systematic review and meta-analysis. Acta Ophthalmol. May 2024;102(3):263-273. [CrossRef] [Medline]
  14. Cupples ME, Hart PM, Johnston A, Jackson AJ. Improving healthcare access for people with visual impairment and blindness. BMJ. Jan 30, 2012;344(jan30 1):e542. [CrossRef] [Medline]
  15. Kim HN. Mobile health technology accessible to people with visual impairments. J Technol Pers Disabil. 2019;7. URL: http://hdl.handle.net/10211.3/210387 [Accessed 2026-09-18]
  16. Rodin A, Shachak A, Miller A, Akopyan V, Semenova N. Mobile apps for eye care in Canada: an analysis of the iTunes store. JMIR Mhealth Uhealth. Jun 14, 2017;5(6):e84. [CrossRef] [Medline]
  17. Evans JR, Fletcher AE, Wormald RPL. Depression and anxiety in visually impaired older people. Ophthalmology. Feb 2007;114(2):283-288. [CrossRef]
  18. Sturrock BA, Xie J, Holloway EE, et al. The prevalence and determinants of desire for and use of psychological support in patients with low vision. Asia Pac J Ophthalmol (Phila). 2014;3(5):286-293. [CrossRef] [Medline]
  19. van der Aa HPA, Hoeben M, Rainey L, van Rens GHMB, Vreeken HL, van Nispen RMA. Why visually impaired older adults often do not receive mental health services: the patient’s perspective. Qual Life Res. Apr 2015;24(4):969-978. [CrossRef] [Medline]
  20. Withers J, Speight C. Health care for individuals with hearing loss or vision loss. N C Med J. Mar 2017;78(2):107-112. [CrossRef]
  21. Burton DM, Uslan MM, Blubaugh MV, Clements CW 3rd. Are current insulin pumps accessible to blind and visually impaired people? J Diabetes Sci Technol. May 1, 2009;3(3):613-618. [CrossRef] [Medline]
  22. Martín ISM, Fernández MG, Yurrita LC. Mobile applications for nutrition, dietetics and healthy habits; analysis and consequences of an increasing trend [Article in Spanish]. Nutr Hosp. 2014;30(1):15-24. [CrossRef]
  23. de la Vega R, Roset R, Castarlenas E, Sánchez-Rodríguez E, Solé E, Miró J. Development and testing of painometer: a smartphone app to assess pain intensity. J Pain. Oct 2014;15(10):1001-1007. [CrossRef] [Medline]
  24. Miró J, Lleixà-Daga M, de la Vega R, Llorens-Vernet P, Jensen MP. A mobile application to help self-manage pain severity, anxiety, and depressive symptoms in patients with fibromyalgia syndrome: a pilot study. Int J Environ Res Public Health. Sep 23, 2022;19(19):12026. [CrossRef] [Medline]
  25. El-Sappagh S, Ali F, El-Masri S, Kim K, Ali A, Kwak KS. Mobile health technologies for diabetes mellitus: current state and future challenges. IEEE Access. 2018;7:21917-21947. [CrossRef]
  26. Thangada ND, Garg N, Pandey A, Kumar N. The emerging role of mobile-health applications in the management of hypertension. Curr Cardiol Rep. Jul 26, 2018;20(9):78. [CrossRef] [Medline]
  27. Martín-Martín J, Muro-Culebras A, Roldán-Jiménez C, et al. Evaluation of Android and Apple Store depression applications based on Mobile Application Rating Scale. Int J Environ Res Public Health. Nov 27, 2021;18(23):12505. [CrossRef] [Medline]
  28. Firth J, Torous J, Nicholas J, Carney R, Rosenbaum S, Sarris J. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. J Affect Disord. Aug 15, 2017;218:15-22. [CrossRef] [Medline]
  29. Al-Razgan M, Almoaiqel S, Alrajhi N, et al. A systematic literature review on the usability of mobile applications for visually impaired users. PeerJ Comput Sci. 2021;7:e771. [CrossRef] [Medline]
  30. de la Vega R, Miró J. mHealth: a strategic field without a solid scientific soul. a systematic review of pain-related apps. PLoS One. 2014;9(7):e101312. [CrossRef] [Medline]
  31. Groen G, Jörns-Presentati A, Dessauvagie A, et al. Development of a mobile application for detection of adolescent mental health problems and feasibility assessment with primary health care workers. Issues Ment Health Nurs. Nov 2022;43(11):1046-1055. [CrossRef] [Medline]
  32. Horton EL, Renganathan R, Toth BN, et al. A review of principles in design and usability testing of tactile technology for individuals with visual impairments. Assist Technol. 2017;29(1):28-36. [CrossRef] [Medline]
  33. Morris JT, Sweatman WM, Jones ML. Smartphone use and activities by people with disabilities: user survey 2016. J Technol Pers Disabil. 2017. URL: https:/​/portal.​qader.org/​cached_uploads/​download/​2018/​07/​07/​smartphones-used-by-people-with-disabilites-1530943057.​pdf [Accessed 2026-10-06]
  34. Llorens-Vernet P, Miró J. The Mobile App Development and Assessment Guide (MAG): Delphi-based validity study. JMIR Mhealth Uhealth. Jul 31, 2020;8(7):e17760. [CrossRef] [Medline]
  35. Llorens-Vernet P, Miró J. Standards for mobile health-related apps: systematic review and development of a guide. JMIR Mhealth Uhealth. Mar 3, 2020;8(3):e13057. [CrossRef] [Medline]
  36. Huckvale K, Prieto JT, Tilney M, Benghozi PJ, Car J. Unaddressed privacy risks in accredited health and wellness apps: a cross-sectional systematic assessment. BMC Med. Dec 2015;13(1):1-13. [CrossRef]
  37. Miró J, Llorens-Vernet P. Assessing the quality of mobile health-related apps: interrater reliability study of two guides. JMIR Mhealth Uhealth. Apr 19, 2021;9(4):e26471. [CrossRef] [Medline]
  38. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Mar 29, 2021;372:n71. [CrossRef] [Medline]
  39. PROSPERO: international prospective register of systematic reviews. Centre for Reviews and Dissemination, University of York; 2025. URL: https://www.crd.york.ac.uk/prospero/ [Accessed 2026-10-06]
  40. Farley JB, Stein J, Keogh JWL, Woods CT, Milne N. The relationship between physical fitness qualities and sport-specific technical skills in female, team-based ball players: a systematic review. Sports Med Open. Apr 15, 2020;6(1):18. [CrossRef] [Medline]
  41. Garriga-Cazorla H, Roman-Juan J, Martí L, Solé E, Martínez-Leal R, Miró J. Chronic pain in autism. Clin J Pain. 2025;41(8). [CrossRef]
  42. Martí L, Garriga-Cazorla H, Roman-Juan J, Miró J. Family-related factors in children and adolescents with chronic pain: a systematic review. Eur J Pain. Jul 2025;29(6):e70038. [CrossRef] [Medline]
  43. Web Content Accessibility Guidelines (WCAG) 21 W3C recommendation. World Wide Web Consortium (W3C). Jun 5, 2018. URL: https://www.w3.org/TR/WCAG21/ [Accessed 2025-10-02]
  44. Nedovic T, Umeri-Sali N, Denecke K. Supporting blind and visually impaired persons in managing their medication. Stud Health Technol Inform. Sep 3, 2019;267:189-196. [CrossRef] [Medline]
  45. Nimmolrat A, Khuwuthyakorn P, Wientong P, Thinnukool O. Pharmaceutical mobile application for visually-impaired people in Thailand: development and implementation. BMC Med Inform Decis Mak. Jul 16, 2021;21(1):217. [CrossRef] [Medline]
  46. Morawski K, Ghazinouri R, Krumme A, et al. Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP randomized clinical trial. JAMA Intern Med. Jun 1, 2018;178(6):802-809. [CrossRef] [Medline]
  47. Grady M, Cameron H, Holt E. Sustained improvements in readings in-range using an advanced Bluetooth® connected blood glucose meter and a mobile diabetes app: real-world evidence from more than 55,000 people with diabetes. Diabetes Ther. Jun 2023;14(6):1023-1035. [CrossRef] [Medline]
  48. Merino Torres JF, Grady M, Lopez Alba A, et al. Clinical practice experiences using a professional diabetes management ecosystem during COVID. J Diabetes Sci Technol. Mar 2023;17(2):390-399. [CrossRef] [Medline]
  49. Banal MG, Bongga D, Angbengco JM, Amarra S, Panlasigui L. MyFitnessPal smartphone application: relative validity and intercoder reliability among dietitians in assessing energy and macronutrient intakes of selected Filipino adults with obesity. BMJ Nutr Prev Health. 2024;7(1):54-60. [CrossRef] [Medline]
  50. Shade M, Boron J, Manley N, Kupzyk K, Pullen C. Ease of use and usefulness of medication reminder apps among rural aging adults. J Community Health Nurs. 2019;36(3):105-114. [CrossRef] [Medline]
  51. Choi S, Seo JY, Krishnan A, Kamath S, Kitsiou S, Haegele J. Development of a personalized conversational health agent to enhance physical activity for blind and low-vision individuals. Mhealth. 2025;11:29. [CrossRef] [Medline]
  52. González Oñate C, Fanjul Peyró C. Mobile applications for the elderly: a study of their current strategy [Article in Spanish]. RIFIE. 2018;47(1):107. [CrossRef]
  53. Spektor T, Nikolic N, Lekakh O, Gaynes BI. Efficacy of ScripTalk automated prescription label reader and veterans with visual impairments. J Vis Impair Blind. Sep 2015;109(5):412-418. [CrossRef]
  54. Bee YM, Batcagan-Abueg APM, Chei CL, et al. A smartphone application to deliver a treat-to-target insulin titration algorithm in insulin-naive patients with type 2 diabetes: a pilot randomized controlled trial. Diabetes Care. Oct 2016;39(10):e174-e176. [CrossRef] [Medline]
  55. Gordon M, Althoff T, Leskovec J. Goal-setting and achievement in activity tracking apps: a case study of MyFitnessPal. 2019. Presented at: WWW '19: The World Wide Web Conference; May 13-17, 2019:571-582; San Francisco CA USA. [CrossRef]
  56. Kao K, Brandner L, Virdi N. Comparison of glucose metrics between users of CGM readers and CGM-connected apps. J Diabetes Sci Technol. Jan 2022;16(1):259-260. [CrossRef] [Medline]
  57. Inal Y, Wake JD, Guribye F, Nordgreen T. Usability evaluations of mobile mental health technologies: systematic review. J Med Internet Res. Jan 6, 2020;22(1):e15337. [CrossRef] [Medline]
  58. de la Vega R, Roset R, Galán S, Miró J. Fibroline: a mobile app for improving the quality of life of young people with fibromyalgia. J Health Psychol. Jan 2018;23(1):67-78. [CrossRef] [Medline]
  59. Theodorou P, Tsiligkos K, Meliones A, Filios C. An extended usability and UX evaluation of a mobile application for the navigation of individuals with blindness and visual impairments outdoors-an evaluation framework based on training. Sensors (Basel). Jun 16, 2022;22(12):4538. [CrossRef] [Medline]
  60. Kane SK, Morris MR, Perkins AZ, Wigdor D, Ladner RE, Wobbrock JO. Access overlays: improving non-visual access to large touch screens for blind users. UIST’11: Proceedings of the 24th Annual ACM Symposium on User Interface Software and Technology. Oct 2011:273-282. [CrossRef]
  61. Grussenmeyer W, Folmer E. Accessible touchscreen technology for people with visual impairments. ACM Trans Access Comput. Jun 30, 2017;9(2):1-31. [CrossRef]
  62. W3C Accessibility Guidelines (WCAG) 30 (working draft). World Wide Web Consortium (W3C). Mar 3, 2026. URL: https://www.w3.org/TR/2026/WD-wcag-3.0-20260303/ [Accessed 2026-04-10]


‎
MAG: Mobile App Development and Assessment Guide
NCBI: National Center for Biotechnology Information
NIH: National Institutes of Health
ONCE: Spanish National Organization for the Blind
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
W3C: World Wide Web Consortium
WCAG: Web Content Accessibility Guidelines


Edited by Nazlena Mohamad Ali; submitted 13.Oct.2025; peer-reviewed by Nicole Ross, Sanchita S Kamath; final revised version received 24.Jul.2026; accepted 04.Aug.2026; published 12.Nov.2026.

Copyright

© Carlos Mora, Ester Solé, Pere Llorens-Vernet, Jordi Miró. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 12.Nov.2026.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on https://mhealth.jmir.org/, as well as this copyright and license information must be included.